Development of the new antiasthmatic drugs is directed above all in the synthesis of theinhibitors of the proinflammatory cytokines and IgE antibodies. Several biologic drugs are tested for this purpose; most common of them are monoclonal antibodies or modified recep­tors. Experiments were also done with antiinflammatory cytokines, chemokine inhibitors, antilymphocytic antibodies, cell adhesion blockers and CpG oligonucleotides. The most promis­ing drugs are those directed against interleukines IL-4, IL-5, IL-13, cytokine TNFa and IgE immunoglobulin. Humanized monoclonal antibody directed against immunoglobulin E bind­ing site is the only biologic drug which is already used in the asthma treatment. Better under­standing of the molecular mechanisms of asthma leads to the identification of the new therapeutic targets.